Boston Scientific Corporation $BSX Shares Bought by Baird Financial Group Inc.

Baird Financial Group Inc. lifted its stake in Boston Scientific Corporation (NYSE:BSX) by 13.4% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 273,534 shares of the medical equipment provider’s stock after acquiring an additional 32,417 shares during the quarter. Baird Financial Group Inc.’s holdings in Boston Scientific were worth $29,380,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. 1248 Management LLC purchased a new position in shares of Boston Scientific during the first quarter worth $26,000. Y.D. More Investments Ltd purchased a new position in Boston Scientific during the 1st quarter valued at about $27,000. Sound Income Strategies LLC grew its holdings in shares of Boston Scientific by 90.9% in the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 120 shares in the last quarter. Kilter Group LLC purchased a new stake in shares of Boston Scientific during the second quarter worth $30,000. Finally, Princeton Global Asset Management LLC purchased a new stake in Boston Scientific during the 2nd quarter worth about $32,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Trading Down 0.3%

Shares of Boston Scientific stock opened at $97.46 on Friday. The company has a 50-day moving average of $99.27 and a two-hundred day moving average of $102.07. The stock has a market cap of $144.48 billion, a PE ratio of 52.12, a price-to-earnings-growth ratio of 1.97 and a beta of 0.67. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47. Boston Scientific Corporation has a 12-month low of $85.98 and a 12-month high of $109.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. The business had revenue of $5.07 billion for the quarter, compared to analysts’ expectations of $4.97 billion. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The company’s revenue was up 20.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. On average, research analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Transactions at Boston Scientific

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the completion of the transaction, the executive vice president owned 178,342 shares in the company, valued at approximately $17,739,678.74. The trade was a 21.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the sale, the executive vice president directly owned 23,600 shares in the company, valued at $2,396,580. This trade represents a 42.32% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 143,095 shares of company stock valued at $14,228,950 in the last 90 days. 0.50% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research analysts have recently issued reports on BSX shares. Barclays upped their price objective on Boston Scientific from $133.00 to $136.00 and gave the stock an “overweight” rating in a research report on Thursday, October 2nd. Leerink Partners lifted their target price on Boston Scientific from $127.00 to $128.00 and gave the company an “outperform” rating in a research note on Wednesday, October 1st. Wells Fargo & Company upped their price target on Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a research note on Thursday, October 23rd. BTIG Research reiterated a “buy” rating and issued a $132.00 price objective on shares of Boston Scientific in a research report on Friday, November 21st. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $125.00 price objective on shares of Boston Scientific in a research note on Monday, September 29th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, Boston Scientific presently has a consensus rating of “Buy” and an average target price of $123.77.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.